Veeva Purchases Ostro to Enhance AI-Driven Interactions within the Life Sciences Sector

Veeva Systems Expands AI Capabilities with Ostro Acquisition

Veeva Systems (VEEV) has announced the purchase of Ostro, a platform leveraging artificial intelligence to enhance brand engagement within the life sciences sector. Ostro’s technology allows pharmaceutical companies to deliver instant, compliant responses to both patients and healthcare professionals through conversational AI integrated into brand websites.

Implications for Investors and Veeva’s Commercial Strategy

This acquisition underscores Veeva’s ongoing commitment to integrating AI into its commercial offerings. By incorporating Ostro’s advanced features, Veeva aims to bolster its digital engagement tools for life sciences clients, potentially increasing the appeal and utility of its Commercial Cloud platform and opening up new avenues for long-term growth.

VEEV Stock Performance After the Announcement

Following the news, Veeva’s stock declined by 3.3% in the most recent trading session. Over the past six months, the company’s shares have dropped 34.6%, while the broader industry experienced a 38.2% decrease. In contrast, the S&P 500 index rose by 1.7% during the same timeframe.

Looking ahead, the integration of Ostro’s conversational AI could further solidify Veeva’s position in the evolving landscape of AI-driven customer engagement for life sciences. The addition of real-time, compliant communication tools is expected to help pharmaceutical companies respond more efficiently to healthcare providers and patients, while also gathering valuable engagement data. Over time, these enhancements could drive greater adoption of Veeva’s applications and support continued expansion of its commercial software ecosystem.

Veeva Systems currently holds a market capitalization of $30.75 billion.

Image Source: Zacks Investment Research

Details of the Ostro Acquisition

Ostro specializes in AI-powered brand engagement for the life sciences industry, enabling users to interact with an AI chat interface that provides immediate, reliable answers based on approved brand content. The platform combines conversational AI, semantic search, and compliance features tailored to industry regulations, ensuring that all responses meet strict standards required by pharmaceutical companies.

Additionally, Ostro’s system collects engagement data, offering insights into the information needs of patients and healthcare professionals. This data helps life sciences brands refine their outreach and educational initiatives.

Veeva acquired Ostro for approximately $100 million, a combination of cash and long-term equity incentives. Ostro will continue to operate independently under its current leadership, with plans for gradual integration into Veeva’s Commercial Cloud suite.

Industry Outlook for Customer Engagement Solutions

The global market for customer engagement solutions is expected to grow from $26.67 billion in 2026 to $57.45 billion by 2034, reflecting a compound annual growth rate (CAGR) of 10.1%. This expansion is driven by ongoing digital transformation, increased adoption of AI, and the integration of engagement tools into platforms like ERP and CRM systems.

Recent Achievements by Veeva Systems

Veeva recently concluded the fourth quarter of fiscal 2026 with results that exceeded expectations, as both earnings and revenue surpassed analyst estimates. The Subscription Services segment showed particularly strong performance, and growth in Professional Services and other revenue streams was also notable.

VEEV’s Current Zacks Rank and Notable Peers

At present, Veeva holds a Zacks Rank #3 (Hold).

Other top-performing stocks in the broader medical sector include:

• Intuitive Surgical (ISRG): Currently rated Zacks Rank #1 (Strong Buy), Intuitive Surgical reported adjusted EPS of $2.53 for Q4 2025, exceeding expectations by 12.4%. Revenue reached $2.87 billion, 4.7% above estimates. The company’s projected long-term earnings growth rate is 15.7%, outpacing the industry average of 14%.
• Phibro Animal Health (PAHC): With a Zacks Rank #1, Phibro posted adjusted EPS of 87 cents for fiscal Q2 2025, 26.1% above estimates, and revenue of $373.9 million, beating expectations by 4.7%. Its estimated long-term earnings growth rate stands at 21.5%, compared to the industry’s 12.6%.
• Cardinal Health (CAH): Holding a Zacks Rank #2 (Buy), Cardinal Health reported Q2 fiscal 2026 adjusted EPS of $2.63, 10% above consensus, with revenue of $65.6 billion, exceeding estimates by 0.9%. The company’s long-term earnings growth rate is projected at 15%, ahead of the industry’s 9.1%.

Spotlight: Zacks Top 10 Stocks for 2026

There’s still time to access Zacks’ Top 10 stock picks for 2026, curated by Director of Research Sheraz Mian. Since its inception in 2012 through November 2025, this portfolio has achieved a remarkable gain of +2,530.8%, significantly outperforming the S&P 500’s +570.3% return.

Sheraz has meticulously selected the top 10 stocks from over 4,400 companies covered by the Zacks Rank for 2026. Early access to these high-potential picks is still available.

For more investment recommendations, you can download Zacks’ “7 Best Stocks for the Next 30 Days” for free.

Free Stock Analysis Reports

• Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
• Cardinal Health, Inc. (CAH): Free Stock Analysis Report
• Veeva Systems Inc. (VEEV): Free Stock Analysis Report
• Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report